Aspyrian Therapeutics, Inc., is a privately funded clinical stage biotechnology company developing a new class of precision targeted oncologic drugs for the treatment of solid tumors based on a new proprietary cancer targeted platform, Photoimmunotherapy. The Company's first product, RM-1929, is in clinical phase 1 testing to treat recurrent Head and Neck Cancer patients.
Looking for a particular Aspyrian Therapeutics, Inc employee's phone or email?
The Aspyrian Therapeutics, Inc annual revenue was $50.4 million in 2026.
Suzane san is the Chief People Officer of Aspyrian Therapeutics, Inc.
109 people are employed at Aspyrian Therapeutics, Inc.
Aspyrian Therapeutics, Inc is based in San Diego, California.
The NAICS codes for Aspyrian Therapeutics, Inc are [325, 5417, 541, 32, 32541, 54, 3254].
The SIC codes for Aspyrian Therapeutics, Inc are [283, 28].